Valbonne, France, September 22, 2014. – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it will participate at the Société Générale Healthcare & Biotechnology Conference. The conference will be held in Paris on the 24th September 2014.
At the conference, TxCell’s CEO, Damian Marron will give an update on the status and progress for the company’s portfolio of economically viable personalized cell-based immunotherapy products in a range of group and one on one meetings with investors.
“The Société Générale Healthcare & Biotechnology Conference is an important date in the calendar for a wide range of investors and as a result will be an ideal occasion to provide updates to investors on the progress of TxCell,” said Damian Marron, CEO, TxCell. “This includes actions TxCell has taken since our introduction on the Paris Euronext markets. We will also discuss developments concerning our innovative proprietary technological platform ASTrIA of personalized cell-based immunotherapies for severe chronic inflammatory and autoimmune diseases.”
About TxCell
TxCell is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary ASTrIA technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has completed a phase I/IIa study of its lead product candidate, Ovasave® in refractory Crohn’s disease patients and has reported good tolerability and positive clinical efficacy. The company plans to initiate a phase IIb study in the same patient population. TxCell has a strategic partnership for Ovasave with the Swiss company Ferring International Center. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 49 employees based at its headquarters and at its manufacturing site in Besançon.
For more information, please visit www.txcell.com
Help employers find you! Check out all the jobs and post your resume.
